T1	intervention 10 19	Metformin
T2	No-of-participants 453 456	200
T3	eligibility 457 515	nondiabetic patients diagnosed with invasive breast cancer
T4	control 559 566	placebo
T5	outcome-Measure 716 720	LCIS
T6	outcome-Measure 722 753	ductal carcinoma in situ (DCIS)
T7	outcome-Measure 759 782	ductal hyperplasia (DH)
T8	outcome 960 989	median posttreatment Ki-67 LI
T9	intervention-value 1048 1051	15%
T10	control-value 1066 1068	5%
T11	outcome 1075 1082	in LCIS
T12	intervention-value 1094 1097	12%
T13	control-value 1112 1115	10%
T14	outcome 1123 1130	in DCIS
T15	intervention-value 1146 1148	3%
T16	control-value 1162 1164	3%
T17	outcome 1171 1176	in DH
T18	outcome 1197 1246	posttreatment Ki-67 in HER2-positive DCIS lesions
T19	intervention-value 1340 1343	22%
T20	control-value 1359 1362	35%
T21	outcome 1371 1392	in HER2-positive DCIS
T22	intervention-value 1412 1415	12%
T23	control-value 1430 1433	32%
T24	outcome 1442 1475	in ER-positive/HER2-positive DCIS
T25	outcome 1564 1586	invasive breast cancer
